Clinical Trial Update: Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating pemafibrate (K-808) for primary biliary cholangitis in patients with inadequate response to UDCA and/or obeticholic a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• K-808 (pemafibrate)

Snippet

Sponsor: Kowa Research Institute, Inc. | Conditions: Primary Biliary Cholangitis | Phase 2 | Status: ACTIVE_NOT_RECRUITING